JP2022512958A - トランス共刺激分子と組み合わされた抗ｇｐｃ３キメラ抗原受容体（ｃａｒ）及びその治療的用途 - Google Patents

トランス共刺激分子と組み合わされた抗ｇｐｃ３キメラ抗原受容体（ｃａｒ）及びその治療的用途 Download PDF

Info

Publication number
JP2022512958A
JP2022512958A JP2021524959A JP2021524959A JP2022512958A JP 2022512958 A JP2022512958 A JP 2022512958A JP 2021524959 A JP2021524959 A JP 2021524959A JP 2021524959 A JP2021524959 A JP 2021524959A JP 2022512958 A JP2022512958 A JP 2022512958A
Authority
JP
Japan
Prior art keywords
cells
car
polypeptide
domain
gpc3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021524959A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512958A5 (enExample
Inventor
マクギネス キャスリーン
ウィルソン チャールズ
ヘリン ブラント
モッツ グレゴリー
Original Assignee
ソティオ，リミティド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソティオ，リミティド ライアビリティ カンパニー filed Critical ソティオ，リミティド ライアビリティ カンパニー
Publication of JP2022512958A publication Critical patent/JP2022512958A/ja
Publication of JP2022512958A5 publication Critical patent/JP2022512958A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021524959A 2018-11-07 2019-11-07 トランス共刺激分子と組み合わされた抗ｇｐｃ３キメラ抗原受容体（ｃａｒ）及びその治療的用途 Pending JP2022512958A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862756683P 2018-11-07 2018-11-07
US62/756,683 2018-11-07
PCT/US2019/060287 WO2020097346A1 (en) 2018-11-07 2019-11-07 ANTI-GPC3 CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF

Publications (2)

Publication Number Publication Date
JP2022512958A true JP2022512958A (ja) 2022-02-07
JP2022512958A5 JP2022512958A5 (enExample) 2022-11-11

Family

ID=70611157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021524959A Pending JP2022512958A (ja) 2018-11-07 2019-11-07 トランス共刺激分子と組み合わされた抗ｇｐｃ３キメラ抗原受容体（ｃａｒ）及びその治療的用途

Country Status (7)

Country Link
US (1) US20220054545A1 (enExample)
EP (1) EP3876950A4 (enExample)
JP (1) JP2022512958A (enExample)
CN (1) CN113260368B (enExample)
AU (1) AU2019374828A1 (enExample)
CA (1) CA3118889A1 (enExample)
WO (1) WO2020097346A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN110468105B (zh) * 2018-05-09 2024-03-22 恺兴生命科技(上海)有限公司 表达il-18r结合蛋白的免疫效应细胞
WO2020037066A1 (en) 2018-08-14 2020-02-20 Unum Therapeutics Inc. Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof
AU2020437669A1 (en) * 2020-03-26 2022-09-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CD28H domain-containing chimeric antigen receptors and methods of use
CN113754778A (zh) * 2020-06-05 2021-12-07 上海交通大学 靶向cldn18.2的嵌合抗原受体及其用途
CN114057890A (zh) * 2020-07-31 2022-02-18 南京北恒生物科技有限公司 新型共刺激结构域及其用途
CN112159818B (zh) * 2020-08-20 2023-02-21 山东兴瑞生物科技有限公司 用于治疗hcc的核酸、其制备方法、具有该核酸的car-t细胞及细胞的制备方法
US20240041924A1 (en) * 2020-09-29 2024-02-08 Nanjing Legend Biotech Co., Ltd. T cell and antigen-presenting cell engagers and uses thereof
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
US20240277841A2 (en) * 2020-12-11 2024-08-22 Purdue Research Foundation Human chimeric antigen receptor neutrophils, compositions, kits and methods of use
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
EP4319794A4 (en) * 2021-04-08 2025-03-12 Artiva Biotherapeutics, Inc. CHIMERIC ANTIGEN RECEPTOR COMPRISING AN ANTI-CD19 ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT THEREOF AND NATURAL KILLER CELLS COMPRISING SAME
CA3217252A1 (en) * 2021-04-19 2022-10-27 Nanjing Legend Biotech Co., Ltd. Chimeric cytokine receptors and uses thereof in cellular therapies
CN117615786A (zh) * 2021-05-07 2024-02-27 森蒂生物科学公司 嵌合抗原受体及其使用方法
WO2023036043A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗癌结合分子及其应用
CA3237201A1 (en) 2021-11-16 2023-05-25 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
CN116426483B (zh) * 2021-12-30 2024-02-23 南京紫珑生物科技有限公司 Cd258蛋白在免疫治疗中的应用
WO2024015995A2 (en) * 2022-07-15 2024-01-18 Albert Einstein College Of Medicine Chimeric antigen receptors comprising a tmigd2 costimulatory domain and associated methods of using the same
CN117304343B (zh) * 2023-10-11 2024-05-07 北京景达生物科技有限公司 Gpc3靶向的car-nk细胞的制备及其应用
CN117247466B (zh) * 2023-11-20 2025-01-24 北京艺妙神州医药科技有限公司 抗磷脂酰肌醇蛋白聚糖3的嵌合抗原受体及其用途
AU2024415858A1 (en) * 2023-12-27 2026-07-16 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of il15 and light
WO2025191139A1 (en) * 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of her2-specific antigen binding proteins and cytokines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112626A1 (en) * 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
WO2017002934A1 (ja) * 2015-07-01 2017-01-05 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013070468A1 (en) * 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
CN104140974B (zh) * 2013-05-08 2017-09-29 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
ES2851123T1 (es) * 2014-09-26 2021-09-03 Baylor College Medicine Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112626A1 (en) * 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
WO2017002934A1 (ja) * 2015-07-01 2017-01-05 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICAL CANCER RESEARCH, JPN6023045338, 2014, ISSN: 0005360463 *

Also Published As

Publication number Publication date
CA3118889A1 (en) 2020-05-14
WO2020097346A1 (en) 2020-05-14
US20220054545A1 (en) 2022-02-24
EP3876950A1 (en) 2021-09-15
EP3876950A4 (en) 2022-11-30
CN113260368A (zh) 2021-08-13
CN113260368B (zh) 2023-08-29
AU2019374828A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
CN113260368B (zh) 抗gpc3嵌合抗原受体(car)与反式共刺激分子的组合及其治疗用途
AU2019299439C1 (en) Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
US20240376442A1 (en) Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof
US20210340219A1 (en) Chimeric receptor polypeptides in combination with trans metabolism molecules modulating intracellular lactate concentrations and therapeutic uses thereof
US20210261646A1 (en) Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
US20240390495A1 (en) Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
CA2969384A1 (en) Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
WO2020028572A2 (en) ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF
US20250297022A1 (en) Engineered switches for immune cell activity and methods of use thereof
JP2024504048A (ja) 発現が増加した変異細胞内ドメインを含むキメラ共刺激タンパク質
US20260053924A1 (en) Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024215987A1 (en) IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
US20250073268A1 (en) Chimeric cd40 polypeptides and methods of use in immunotherapy
WO2024215989A1 (en) ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS
WO2024040207A1 (en) Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221102

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240702